Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: ValuEngine, Inc.
|
$127.00
|
|
Provider: Market Edge
|
$10.00
|
|
Provider: Zacks Investment Research Inc.
|
$12.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Sarepta Therapeutics Inc Announces Pricing Of $125 Million Public Offering Of Common Stock
Sarepta Therapeutics Inc announced that it has priced an underwritten public offering of an aggregate of 4,950,495 shares of its common stock at a price to the public of $25.25 per share. In addition, Sarepta has granted the underwriters a 30-day option to purchase up to an additional 742,574 shares of common stock on the same terms and conditions, solely to cover over-allotments, if any. Sarepta anticipates the aggregate net proceeds from the offering will be approximately $118.2 million, after deducting the underwriting discount and estimated offering expenses payable by Sarepta, but excluding any exercise of the underwriters' over-allotment option. The offering is expected to close on or about December 18, 2012, subject to customary closing conditions.
Latest Developments for Sarepta Therapeutics Inc
- Sarepta Therapeutics Inc Issues FY 2013 Guidance Below Analysts' Estimates
- Sarepta Therapeutics Inc Announces Proposed Public Offering Of Common Stock
- Sarepta Therapeutics Inc Announces Continued Benefit On Walking Test Through 62 Weeks In Phase IIb Open-Label Extension Study of Eteplirsen In Duchenne Muscular Dystrophy
- Sarepta Therapeutics Inc Sees FY 2012 Revenue Guidance At Low End Of Prior Range; Reaffirms FY 2012 Earnings Guidance
Latest Key Developments in Pharmaceuticals
- Share this
- Link this
- Digg this


Follow Reuters